CHENGDU, China,
July 2, 2018 /PRNewswire/ -- Sanofi
(EURONEXT: SAN) (NYSE: SNY) is launching a Global R&D
Operations Hub with a specialized focus on digitalization and big
data analysis in Chengdu,
Sichuan province, China. The new R&D operations hub confirms
China as the third pillar of
Sanofi Global Clinical Sciences and Operations, joining facilities
in France and the United States.
With an investment of €66 million, the Hub will support
the clinical research and development of Sanofi's innovative drugs
by focusing on the management of global multi-center clinical
trials data and files. Bringing together global data and analysis,
the Hub will accelerate the availability of trial results, from
Phase I to Phase IV. The Hub will take advantage of local talents
to further strengthen Sanofi's digital capabilities.
"Through this new Hub, we
will take full advantage of our global experience and R&D
capabilities together with local scientific research strengths to
further improve innovation," said
Zhang Ji, Ph.D., Senior Vice
President, Global Head of Sanofi R&D Operations. "Our goal
is to link China's innovative
achievements with the global ecosystem and develop innovative drugs
in China that could benefit
patients around the world."
The Chengdu Hub will target diseases that affect millions
of people across our therapeutic areas: diabetes and cardiovascular
diseases, vaccines, oncology, immunology and inflammation, rare
diseases, multiple sclerosis and neurology. It will leverage global
cutting-edge biological technology for polypeptides, gene therapy,
monoclonal antibodies and multi-specific antibodies. The Hub plans
to recruit 300 local pharmaceutical research and development
professionals by 2020.
About Sanofi China
Sanofi China, established in 1982 with headquarters in
Shanghai, has a wide range of
businesses covering pharmaceuticals and human vaccines (Sanofi
Pasteur). The group has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fuzhou and Urumqi, and three production bases
in Beijing, Hangzhou, and Shenzhen. At the end of 2017, Sanofi had over
9,500 employees in China.
With the China R&D Center and the Asia-Pacific R&D
Center in Shanghai, Sanofi
possesses an overall R&D capability, from drug targets to
clinical trials, and has been focusing on frequently occurring
diseases like liver diseases, diabetes, cancers and cardiovascular
diseases in China and the
Asia-Pacific region.
Please visit www.sanofi.cn for
more information.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Media Relations Contact Ashleigh
Koss
Tel.: 908-981-8745
mr@sanofi.com
|
|
|
Investor Relations Contact George
Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/sanofi-to-further-accelerate-its-scientific-presence-with-the-opening-of-a-global-rd-operations-hub-in-chengdu-china-300675107.html
SOURCE Sanofi